| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Comprehensive Epilepsy Program (Dr. Delgado-Escueta), Department of Neurology, UCLA School of Medicine, Los Angeles, CA, the Southwest Regional Epilepsy Center (Dr. Delgado-Escueta), Neurology Service, West Los Angeles VA Medical Center, Wadsworth Division, Los Angeles, CA, and Public Health Service Fellow (Fogarty International) (Dr. Enrile-Bacsal), Section of Neurology, University of the Philippines College of Medicine, Taft Avenue, Manila, Philippines.
We studied 43 patients, aged 15 to 69 years, whose convulsive seizures were uncontrolled because the syndrome of juvenile myoclonic epilepsy was not recognized. Awakening myoclonic jerks appeared with tonic-clonic (18 patients), clonic-tonic-clonic (24 patients), and absence seizures (17 patients), with a mean age at onset of 13.6 years. Generalized seizures were present in relatives of 17 patients. All patients had diffuse 3 1/2- to 6-Hz multispike-wave complexes. Valproic acid stopped convulsions in 86% of patients. After being free of seizures for 2 years, withdrawal of valproic acid was followed by relapse of convulsions in 12 patients.
Address correspondence and reprint requests to Dr. Delgado-Escueta, Comprehensive Epilepsy Program, Department of Neurology. UCLA School of Medicine, Los Angeles, CA 90024.
Supported in part by Department of Health and Human Services contract No. N01-NS-0-2332.
Accepted for publication June 17, 1983.
This article has been cited by other articles:
|
|
 |
|
  B. Baykan, E. A. Altindag, N. Bebek, A. Y. Ozturk, B. Aslantas, C. Gurses, I. Baral-Kulaksizoglu, and A. Gokyigit Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy Neurology, May 27, 2008; 70(22_Part_2): 2123 - 2129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Medina, T. Suzuki, M. E. Alonso, R. M. Duron, I. E. Martinez-Juarez, J. N. Bailey, D. Bai, Y. Inoue, I. Yoshimura, S. Kaneko, et al. Novel mutations in Myoclonin1/EFHC1 in sporadic and familial juvenile myoclonic epilepsy Neurology, May 27, 2008; 70(22_Part_2): 2137 - 2144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Martinez-Juarez, M. E. Alonso, M. T. Medina, R. M. Duron, J. N. Bailey, M. Lopez-Ruiz, R. Ramos-Ramirez, L. Leon, G. Pineda, I. P. Castroviejo, et al. Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up Brain, May 1, 2006; 129(5): 1269 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Vijai, A Kapoor, H M Ravishankar, P J Cherian, G Kuruttukulam, B Rajendran, R Sridharan, G Rangan, A S Girija, S Jayalakshmi, et al. Protective and susceptibility effects of hSKCa3 allelic variants on juvenile myoclonic epilepsy J. Med. Genet., May 1, 2005; 42(5): 439 - 442. [Full Text] [PDF]
|
|
|
|
 |
|
 N Adab, U Kini, J Vinten, J Ayres, G Baker, J Clayton-Smith, H Coyle, A Fryer, J Gorry, J Gregg, et al. The longer term outcome of children born to mothers with epilepsy J. Neurol. Neurosurg. Psychiatry, November 1, 2004; 75(11): 1575 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Mas, N Taske, S Deutsch, M Guipponi, P Thomas, A Covanis, M Friis, M J Kjeldsen, G P Pizzolato, J-G Villemure, et al. Association of the connexin36 gene with juvenile myoclonic epilepsy J. Med. Genet., July 1, 2004; 41(7): e93 - e93. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prasad, R. I. Kuzniecky, R. C. Knowlton, T. E. Welty, R. C. Martin, M. Mendez, and R. E. Faught Evolving Antiepileptic Drug Treatment in Juvenile Myoclonic Epilepsy Arch Neurol, August 1, 2003; 60(8): 1100 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Sheth Adolescent Issues in Epilepsy J Child Neurol, February 1, 2002; 17(2_suppl): 2S23 - 2S27. [Abstract] [PDF]
|
|
|
|
|
|
P. Genton and P. Gelisse Juvenile Myoclonic Epilepsy Arch Neurol, September 1, 2001; 58(9): 1487 - 1490. [Full Text] [PDF]
|
|
|
|
|
|
P Gelisse, P Genton, P Thomas, M Rey, J C Samuelian, and C Dravet Clinical factors of drug resistance in juvenile myoclonic epilepsy J. Neurol. Neurosurg. Psychiatry, February 1, 2001; 70(2): 240 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Genton, P. Gelisse, P. Thomas, and C. Dravet Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology, October 24, 2000; 55(8): 1106 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Matsuoka, T. Takahashi, M. Sasaki, K. Matsumoto, S. Yoshida, Y. Numachi, H. Saito, T. Ueno, and M. Sato Neuropsychological EEG activation in patients with epilepsy Brain, February 1, 2000; 123(2): 318 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. So, E. A. Thiele, T. Sanger, R. Schmid, and J. J. Riviello Jr Electroencephalogram and Clinical Focalities in Juvenile Myoclonic Epilepsy J Child Neurol, November 1, 1998; 13(11): 541 - 545. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Chadwick Controversies in Management: Case for early treatment is not established BMJ, January 21, 1995; 310(6973): 177 - 178. [Full Text]
|
|
|
|
|
|
A.O. Ogunyemi and F.E. Dreifuss Syndromes of Epilepsy in Childhood and Adolescence J Child Neurol, July 1, 1988; 3(3): 214 - 224. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
